The lncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer
Metrics: PDF 3571 views | HTML 3676 views | ?
John R. Prensner1,*, Anirban Sahu1,*, Matthew K. Iyer1,2,*, Rohit Malik1,*, Benjamin Chandler1, Irfan A. Asangani1, Anton Poliakov1, Ismael A. Vergara3, Mohammed Alshalalfa3, Robert B. Jenkins4, Elai Davicioni3, Felix Y. Feng1,5,7, Arul M. Chinnaiyan1,2,6,7,8
1 Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan USA.
2 Department of Computational Medicine and Bioinformatics, Ann Arbor, Michigan USA.
3 GenomeDx Biosciences Inc., Vancouver, British Columbia, Canada.
4 Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota USA.
5 Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan USA.
6 Department of Pathology, University of Michigan, Ann Arbor, Michigan USA.
7 Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan USA.
8 Howard Hughes Medical Institute, University of Michigan, Ann Arbor, Michigan USA.
* These authors contributed equally
Arul M. Chinnaiyan, email:
Keywords: prostate cancer, long noncoding RNA, androgen receptor
Received: February 5, 2014 Accepted: March 21, 2014 Published: March 23, 2014
Long noncoding RNAs (lncRNAs) are increasingly implicated in cancer biology, contributing to essential cancer cell functions such as proliferation, invasion, and metastasis. In prostate cancer, several lncRNAs have been nominated as critical actors in disease pathogenesis. Among these, expression of PCGEM1 and PRNCR1 has been identified as a possible component in disease progression through the coordination of androgen receptor (AR) signaling (Yang et al., Nature 2013, see ref. ). However, concerns regarding the robustness of these findings have been suggested. Here, we sought to evaluate whether PCGEM1 and PRNCR1 are associated with prostate cancer. Through a comprehensive analysis of RNA-sequencing data (RNA-seq), we find evidence that PCGEM1 but not PRNCR1 is associated with prostate cancer. We employ a large cohort of >230 high-risk prostate cancer patients with long-term outcomes data to show that, in contrast to prior reports, neither gene is associated with poor patient outcomes. We further observe no evidence that PCGEM1 nor PRNCR1 interact with AR, and neither gene is a component of AR signaling. Thus, we conclusively demonstrate that PCGEM1 and PRNCR1 are not prognostic lncRNAs in prostate cancer and we refute suggestions that these lncRNAs interact in AR signaling.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.